Please assess the completion status of the following clinical trial:

Trial Title: The Purpose of This Study is to Determine if Tetrodotoxin (TTX) is Effective in the Treatment of Pain Resulting From Chemotherapy Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* If female, not of childbearing potential.~* Patients with documented neuropathic pain~* Cancer Patients who have completed a chemotherapy regimen which included taxanes or platinums (or both) and have no evidence actively progressive disease. Concurrent hormonal therapies are allowed~* Patients with stable moderate to severe neuropathic pain~* Patients with an Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.~* Patients who are able to complete the study-related questionnaires independently in either English or Spanish.~Exclusion Criteria:~* History of peripheral neuropathy attributed to any cause other than chemotherapy.~* Patients receiving any concurrent agents known to cause peripheral neuropathy within 30 days of Randomization.~* Current use of other therapy (ies), including alternative therapies, for treatment of peripheral neuropathy within 30 days of Randomization (with the exception of protocol allowed concurrent medications).~* Patients who used controlled release opioids within seven days of baseline period or who expect to use controlled release opioids at any time from baseline to end of study.~* Patients with abnormal kidney function.~* Patients with bone metastases.~* Patients scheduled for treatment for their cancer with chemotherapy or radiotherapy between screening and the end of study visit.~* Current use of lidocaine and other types of antiarrhythmic drugs within 30 days of Randomization.~* Current use of scopolamine and acetylcholinesterase-inhibiting drugs such as physostigmine within 30 days of Randomization.~* Current cause of Chemotherapy Induced Neuropathic Pain attributed to Velcade (Bortezomib) or vinca alkaloids or analogues such as vincristine, vinblasine, vinorelbine and vindesine.~* Current use of tricyclic antidepressant medication, anticonvulsants and monoamine oxidase inhibitors.~* Patients with current uncontrolled asthma or lung disease.~* Patients with significant heart disease.~* Use of an investigational agent within 30 days prior to screening or is scheduled to receive an investigational drug other than TTX during the course of the study.~* Females who are pregnant or nursing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (twice daily) (Type: PLACEBO_COMPARATOR): Placebo for injection (1 ml volume), twice a day for four consecutive days.
- Low dose Tetrodotoxin (twice daily) (Type: EXPERIMENTAL): Low dose Tetrodotoxin injectable (1 ml volume), twice a day for four consecutive days.
- Mid-range dose of Tetrodotoxin (twice daily) (Type: EXPERIMENTAL): Mid-range dose Tetrodotoxin injectable (1 ml volume), twice a day for four consecutive days.
- Max dose Tetrodotoxin (once daily) (Type: EXPERIMENTAL): Max dose Tetrodotoxin injectable (1 ml volume), once a day in the morning for four consecutive days and Placebo for injection (1 ml volume), once a day in the afternoon for four consecutive days. Total of 4 treatment days.
- Max dose Tetrodotoxin (twice daily) (Type: EXPERIMENTAL): Max dose Tetrodotoxin injectable (1 ml volume), twice a day for four consecutive days.

Based on this trial design, predict the completion outcome and termination type (if applicable).